semaglutide compounding news november 2025 Beyond the Headlines: FDA Warning Letters to GLP-1 Compounders Compounded Semaglutide 2 Month Program

EQ-5D, EuroQoL-5D

Louisans have heard about these concerns In this weeks survey, 28% of St

shows that approximately one in eight adults (12%) have used a GLP-1 agonist at some point, including 6% who said they are currently using one of these medications

But if you walk in and say "My BMI is 32, I have been diagnosed with prediabetes, and I would like to discuss GLP-1 receptor agonists as part of a comprehensive treatment plan," the doctor hears a medically informed patient requesting evidence-based treatment

Clinical actionability (low burden and risk, availability, and effectiveness of interventions) of these variants justifies their reporting to clinicians